MacroGenics, Inc. - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "MacroGenics, Inc. - Product Pipeline Review - 2014" provides data on the MacroGenics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, MacroGenics, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from MacroGenics, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- MacroGenics, Inc. - Brief MacroGenics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MacroGenics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MacroGenics, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the MacroGenics, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate MacroGenics, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of MacroGenics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MacroGenics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MacroGenics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MacroGenics, Inc. and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
MacroGenics, Inc. Snapshot 5
MacroGenics, Inc. Overview 5
Key Information 5
Key Facts 5
MacroGenics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
MacroGenics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
MacroGenics, Inc. - Pipeline Products Glance 13
MacroGenics, Inc. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
MacroGenics, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
MacroGenics, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
MacroGenics, Inc. - Drug Profiles 18
teplizumab 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
margetuximab 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
MGA-271 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
MGARG-2 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
DART For Autoimmune Disorders 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
MGD-006 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MGD-007 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MGD-010 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
W1-mAb 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
DART mAb 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Mult. mAbs/DARTs 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Multiple Dual-Affinity Re-Targeting Products 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MacroGenics, Inc. - Pipeline Analysis 33
MacroGenics, Inc. - Pipeline Products by Therapeutic Class 33
MacroGenics, Inc. - Pipeline Products by Target 35
MacroGenics, Inc. - Pipeline Products by Route of Administration 37
MacroGenics, Inc. - Pipeline Products by Molecule Type 38
MacroGenics, Inc. - Pipeline Products by Mechanism of Action 39
MacroGenics, Inc. - Recent Pipeline Updates 41
MacroGenics, Inc. - Dormant Projects 45
MacroGenics, Inc. - Company Statement 46
MacroGenics, Inc. - Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
MacroGenics, Inc., Key Information 5
MacroGenics, Inc., Key Facts 5
MacroGenics, Inc. - Pipeline by Indication, 2014 8
MacroGenics, Inc. - Pipeline by Stage of Development, 2014 9
MacroGenics, Inc. - Monotherapy Products in Pipeline, 2014 10
MacroGenics, Inc. - Out-Licensed Products in Pipeline, 2014 11
MacroGenics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
MacroGenics, Inc. - Phase III, 2014 13
MacroGenics, Inc. - Phase II, 2014 14
MacroGenics, Inc. - Phase I, 2014 15
MacroGenics, Inc. - Preclinical, 2014 16
MacroGenics, Inc. - Discovery, 2014 17
MacroGenics, Inc. - Pipeline by Therapeutic Class, 2014 34
MacroGenics, Inc. - Pipeline by Target, 2014 36
MacroGenics, Inc. - Pipeline by Route of Administration, 2014 37
MacroGenics, Inc. - Pipeline by Molecule Type, 2014 38
MacroGenics, Inc. - Pipeline Products by Mechanism of Action, 2014 40
MacroGenics, Inc. - Recent Pipeline Updates, 2014 41
MacroGenics, Inc. - Dormant Developmental Projects,2014 45
MacroGenics, Inc., Other Locations 50
MacroGenics, Inc., Subsidiaries 50